glp-1 news today 2025 november trends 2025: real-world data, patient outcomes & future therapies Who Gets the Shot? GLP-1

The clinical data provides a clear picture of the potential impact of each medication in conjunction with a structured program: Wegovy Weight Loss: Clinical trials show that patients using the highest approved dose achieved an average total body weight loss of approximately 15% over 68 weeks, when combined with diet and exercise

In clinical practice, drug selection should therefore prioritize factors such as tolerability, safety profile, adherence, cost, and patient preference rather than expecting major differences in cardiovascular efficacy

7 In a survey involving 443 physicians, the reasons for discontinuing GLP-1 RAs were investigated in patients who had stopped treatment within the previous six months

Euromonitor International predicts semaglutide-based medications could reshape global food demand over the next decade as cheaper and more widely available versions enter the market

However, both HSA and FSA payments are accepted for all plans, all medications